However, given that ICB with anti-CTLA-4 and anti-PD-1 antibodies functions by promoting T cell activation and the fact that it is currently utilized for the treatment of metastatic melanoma, an investigation of whether TIL subsets can serve as predictive markers for these treatments is of significant clinical value (128). The gene discussed is CTLA4; the disease is metastatic melanoma.